The Life Sciences Innovative Manufacturing Fund (LSIMF) will make up to £520m of grants towards UK Life Sciences manufacturing. LSIMF’s core objectives are to strengthen the UK’s manufacturing capacity and capability to increase health resilience and create economic opportunity. The aim of the fund is to increase the UK’s ability to withstand and recover from health emergencies such as pandemics, long-term healthcare challenges and system shocks such as supply chain disruption. The fund is almost ten times larger than the previous LSIMF, and open for over 5 years.
The LSIMF fund is open UK wide, and all projects which support the fund’s objectives are welcomed. The current round for applications closes at noon on 12 September.
At this stage in the processes, the LSIMF team are especially interested in projects that contribute to pandemic preparedness including increasing production across the range of vaccine modalities, antibodies, antivirals, antibiotics, and diagnostics. At a more granular level, we are currently interested in investments in DNA plasmids, oligonucleotides, antivirals produced with fermentation and active pharmaceutical ingredient manufacturing. We are also interested in critical medicines production, preventative medicines and those that have a significant positive impact on population health via their impact on chronic diseases.
To mark a year since the scheme’s launch, the Office for Life Sciences will be running webinars with trade associations to share learning, highlight particular interests for future rounds, and discuss what makes a strong LSIMF application.
For more information about LSIMF please visit GOV.UK.
For questions about how to apply please email: LSIMF@officeforlifesciences.gov.uk.
